A phase I clinical trial of AZD2171 [cediranib] in children with recurrent or progressive central nervous system (CNS) tumors.
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2016
At a glance
- Drugs Cediranib (Primary)
- Indications CNS cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 04 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.